The ascendancy of Viagra and its impact on the pharmaceutical landscape presents a intricate question for shareholders. While the early sales data were impressive, the patent has lapsed, leading to a deluge of copycat alternatives that are reducing profit. Moreover, the industry is facing difficulties related to demographic trends and shifting h… Read More